DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Alemtuzumab
Alemtuzumab
Alemtuzumab Comparison with Rituximab and Leukemia Whole
Alemtuzumab Comparison with Rituximab and Leukemia Whole
Horizon Scanning Status Report June 2019
Structure–Function Relationships of the Variable Domains of Monoclonal
Monoclonal Antibodies
A Novel Raji-Burkitt's Lymphoma Model for Preclinical and Mechanistic Evaluation of CD52-Targeted Immunotherapeutic Agents
Cetuximab Promotes Anticancer Drug Toxicity in Rhabdomyosarcomas with EGFR Amplificationin Vitro
Antibodies for the Treatment of Brain Metastases, a Dream Or a Reality?
National Drug Monograph Ofatumumab Arzerra September
NMSHP Presentation 2018 Final
125486Orig1s000
Lemtrada, INN-Alemtuzumab
Mabcampath, INN-Alemtuzumab
The Role of Monoclonal Antibodies in the Management of Leukemia
Alemtuzumab, the First, but One of the Most Immunogenic, Humanized Monoclonal Antibodies
Is an in Vitro Whole Blood Cytokine Assay Useful to Detect the Potential Risk of Severe Infusion Reaction of Monoclonal Antibody Pharmaceuticals?
February, 2021
Lemtrada (Alemtuzumab)
Top View
Cutaneous T-Cell Lymphomas
Tumor Lysis Syndrome Caused by Therapeutic Monoclonal Antibodies Approved by FDA
Failure of Alemtuzumab As a Rescue in a NMOSD Patient Treated with Rituximab Markus C
REVIEW ARTICLE Novel Anticancer Monoclonal Antibodies
Open Full Page
Combined Low-Dose Everolimus and Low-Dose Tacrolimus
Peripheral T-Cell Lymphoma: Pharmacotherapy Overview
COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
(CLL/SLL) TREATMENT REGIMENS (Part 1 of 3) Clinical Trials: the NCCN Recommends Cancer Patient Participation in Clinical Trials As the Gold Standard for Treatment
Antibody–Drug Conjugates—A Tutorial Review
Lemtrada (Alemtuzumab)
Bladder Cancer
Subcutaneous Administration of Anticancer Agents
New Immunosuppression Horizons in Kidney Transplantation
"Alemtuzumab" in the Treatment of Multiple Sclerosis
Gazyva® (Obinutuzumab)
Novel Antibodies in the Treatment of Non-Hodgkin's Lymphoma
Uses of Monoclonal Antibodies for the Treatment of Non-Hodgkin
Lenalidomide, Dexamethasone And
Best Practices in Alemtuzumab Administration Practical Recommendations for Infusion in Patients with Multiple Sclerosis
A Xenograft Model of Macrophage Activation Syndrome Amenable to Anti-CD33 and Anti–IL-6R Treatment
Peripheral T-Cell Lymphoma
And Trastuzumab (Herceptin) Using Hyaluronidase
Clinical Opinions
Alemtuzumab) Injection, for Intravenous Use ------CONTRAINDICATIONS------Initial U.S
Adult Antiemetic Management of Chemotherapy-Induced Nausea
E1574.Full.Pdf
Alemtuzumab: What Is the Secret to Safe Therapy?
An Innovative System to Study Immune Responses in Drug Development
1112-01-Grillo-Lopez-11.6.Mm
Obinutuzumab As Frontline Treatment of Chronic Lymphocytic Leukemia: Updated Results of the CLL11 Study
Panitumumab Drug Monograph
(90Y)-Ibritumomab Tiuxetan in Stem Cell Transplantation for Non-Hodgkin’S Lymphoma
Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory and Malignant Disease: Translating TNF-A Experience to Oncology
Use of Monoclonal Antibodies in Oncology
Psoas Abscess Due to Mycobacterium Avium in a Patient with Chronic Lymphocytic Leukemia-Case Report and Review
Brentuximab Vedotin Therapy for Cutaneous
Services and Medicare Part B Drugs These Services May Or May Not Be Covered by Your Healthpartners Plan
Monoclonal Antibodies As Therapeutic Agents in Oncology and Antibody Gene Therapy
Pan-Canadian Oncology Drug Review Initial Clinical Guidance Report
(Arzerra®) for the Treatment of Chronic Lymphocytic Leukaemia in Patients Who Are Refractory to Fludarabine and Alemtuzumab: a Critique of the Submission from GSK
Alemtuzumab (Campath): New Indications the National Marrow Donor Program Board Update
Guidelines for ATC Classification and DDD Assignment 2021
Dose-Escalated Radioimmunotherapy As Part of Reduced Intensity Conditioning for Allogeneic Transplantation in Patients with Advanced High-Grade Non-Hodgkin Lymphoma
Harnessing the Innate Immune System to Treat Cancer: Enhancement of Antibody-Dependent Cellular Cytotoxicity with Anti-CD137 Ab
Trastuzumab (HERCEPTIN) Monograph
HMUD Data Manual
Targeted Approaches to T-Cell Lymphoma
Prescrire's Contribution to OMS Consultation DCI List
UPMC Post-Lung Transplant Care Guidelines
Management Guidelines for the Use of Alemtuzumab in Chronic Lymphocytic Leukemia
Pharmacokinetics of Therapeutic Monoclonal Antibodies Used in Oncology
In Kidney Transplant Patients, Alemtuzumab but Not Basiliximab
Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid Leukemia in the Non-Hematopoietic Stem Cell Transplant Setting
(Ofatumumab) in Fludarabine and Alemtuzumab Refractory Chronic Lymphocytic Leukemia
COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/PBIRG ANATOMICAL CLASSIFICATION
Ofatumumab for the Treatment of Chronic Lymphocytic Leukemia
Alemtuzumab) None (4)
Research Update
Alemtuzumab (Campath-1H) in the Treatment of Chronic Lymphocytic Leukemia
Treatment with Alemtuzumab Or Rituximab After Fingolimod Withdrawal in Relapsing–Remitting Multiple Sclerosis Is Effective and Safe
Alemtuzumab 12Mg/1.2 Ml Concentrate for Solution for Infusion Lemtrada®
Induced Nausea and Vomiting
Arzerra® (Ofatumumab) and Gazyva® (Obinutuzumab)